TMS Co., Ltd.
Stock Price Chart
2026/08/03 UpdatedPrice Trend
2026/08/03 UpdatedPrice & Trading Details
2026/08/03 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/08/01Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/02 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | |
|---|---|
| Income Statement | |
| Revenue | ¥1,947M |
| Gross Profit | - |
| Operating Income | ¥1,136M |
| Pretax Income | ¥1,136M |
| Net Income | ¥1,077M |
| EPS | ¥53.36 |
| Operating Margin | 58.34% |
| Balance Sheet | |
| Total Assets | ¥2,740M |
| Total Equity | ¥2,453M |
| Total Liabilities | ¥287M |
| Cash | ¥2,598M |
| Interest-bearing Debt | - |
| Equity Ratio | 89.53% |
| D/E Ratio | 0.00 |
| Cash Flow | |
| Operating CF | ¥1,262M |
| Investing CF | -¥17M |
| Financing CF | ¥246M |
| Free CF | ¥1,253M |
| Efficiency | |
| ROE | 43.90% |
| ROA | 39.30% |
Latest IR Information
-
Notice on Monthly Exercise Status of the 10th Stock Acquisition Rights (with Exercise Price Adjustment Clause)
Public disclosure of monthly exercise status for stock acquisition rights (with exercise price adjustment clause). Issued shares: 657,800 shares; exercised rights in July: 6,578 units (8.22% of total issued rights); unexercised shares at month-end: 21,135 shares; prior month-end: 27,713 shares....
Read more -
Notice of Monthly Exercise Status for Stock Acquisition Rights (with Exercise Price Revision Clause)
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥620
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. In addition, the company has a collaboration with Hokkaido University to evaluate the potential of the drug candidate compounds as novel drugs. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.
